Distinguished in Virilizing Ovarian Tumor

Dr. Helen L. Frederickson

Obstetrics and Gynecology | Gynecologic Oncology
353 Fairmont Blvd, 
Rapid City, SD 
Accepting New Patients
Distinguished in Virilizing Ovarian Tumor
353 Fairmont Blvd, 
Rapid City, SD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Helen Frederickson is an Obstetrics and Gynecologist and a Gynecologic Oncologist in Rapid City, South Dakota. Dr. Frederickson is rated as a Distinguished provider by MediFind in the treatment of Virilizing Ovarian Tumor. Her top areas of expertise are Endometrial Cancer, Ovarian Carcinosarcoma, Sertoli-Leydig Cell Tumor, Bladder Reconstruction, and Hernia Surgery. Dr. Frederickson is currently accepting new patients.

Her clinical research consists of participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Obstetrics and Gynecology
Gynecologic Oncology
Licenses
Obstetrics & Gynecology in SD
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Avera Health
  • HMO
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO

Locations

353 Fairmont Blvd, Rapid City, SD 57701

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2025
Intervention Type: Other, Drug, Procedure, Biological
Study Drugs: Carboplatin, Paclitaxel, Pembrolizumab
Study Phase: Phase 3
A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma
A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Drug
Study Drug: Tazemetostat
Study Phase: Phase 2
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Atezolizumab, Bevacizumab, Pegylated liposomal doxorubicin hydrochloride
Study Phase: Phase 2/Phase 3
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Enrollment Status: Active_not_recruiting
Publish Date: September 16, 2025
Intervention Type: Procedure, Drug, Other
Study Drugs: Cediranib, Cediranib Maleate, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan, Topotecan Hydrochloride
Study Phase: Phase 2/Phase 3
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
Enrollment Status: Completed
Publish Date: November 07, 2022
Intervention Type: Other, Drug, Radiation
Study Drugs: Carboplatin, Cisplatin, Paclitaxel
Study Phase: Phase 3
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
Enrollment Status: Completed
Publish Date: September 01, 2022
Intervention Type: Other
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
Enrollment Status: Terminated
Publish Date: June 07, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Enrollment Status: Completed
Publish Date: October 20, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 7 Less Clinical Trials
Similar Doctors
Advanced in Virilizing Ovarian Tumor
Dr. Iwona Podzielinski
Gynecologic Oncology | Obstetrics and Gynecology | Oncology
Advanced in Virilizing Ovarian Tumor
Dr. Iwona Podzielinski
Gynecologic Oncology | Obstetrics and Gynecology | Oncology

Monument Health Rapid City Hospital Inc

353 Fairmont Blvd, 
Rapid City, SD 
 (0.1 miles away)
605-755-8109
Languages Spoken:
English, Polish
See accepted insurances
Accepting New Patients
Offers Telehealth

Iwona Podzielinski is a Gynecologic Oncologist and an Obstetrics and Gynecologist in Rapid City, South Dakota. Dr. Podzielinski is rated as a Distinguished provider by MediFind in the treatment of Virilizing Ovarian Tumor. Her top areas of expertise are Endometrial Cancer, Ovarian Cancer, Sertoli-Leydig Cell Tumor, Oophorectomy, and Hysterectomy. Dr. Podzielinski is currently accepting new patients.

Experienced in Virilizing Ovarian Tumor
Dr. Judith K. Wolf
Gynecologic Oncology | Hematology | Oncology
Experienced in Virilizing Ovarian Tumor
Dr. Judith K. Wolf
Gynecologic Oncology | Hematology | Oncology

Monument Health Rapid City Hospital Inc

353 Fairmont Blvd, 
Rapid City, SD 
 (0.1 miles away)
605-755-8109
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Judith Wolf is a Gynecologic Oncologist and a Hematologist in Rapid City, South Dakota. Dr. Wolf is rated as an Advanced provider by MediFind in the treatment of Virilizing Ovarian Tumor. Her top areas of expertise are Malignant Mixed Mullerian Tumor, Endometrial Cancer, Endometrial Stromal Sarcoma, and Ovarian Cancer. Dr. Wolf is currently accepting new patients.

Experienced in Virilizing Ovarian Tumor
Dr. Gunjal Garg
Obstetrics and Gynecology | Gynecologic Oncology | Oncology
Experienced in Virilizing Ovarian Tumor
Dr. Gunjal Garg
Obstetrics and Gynecology | Gynecologic Oncology | Oncology

Monument Health Rapid City Hospital Inc

353 Fairmont Blvd, 
Rapid City, SD 
 (0.1 miles away)
605-755-8109
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Gunjal Garg is an Obstetrics and Gynecologist and a Gynecologic Oncologist in Rapid City, South Dakota. Dr. Garg is rated as an Advanced provider by MediFind in the treatment of Virilizing Ovarian Tumor. Her top areas of expertise are Endometrial Cancer, Ovarian Cancer, Malignant Mixed Mullerian Tumor, Oophorectomy, and Hysterectomy. Dr. Garg is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Frederickson's expertise for a condition
ConditionClose
    View All 9 Distinguished Conditions
    View All 7 Advanced Conditions
    View All 13 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile